Specifically, BCa‐derived EV‐associated miR‐122 was shown to modify glucose utilization by recipient astrocytes through downregulation of the glycolytic enzyme M2‐pyruvate kinase (PKM2) and glucose transporter 1 (GLUT1), leading to enhanced cancer cell proliferation, partially mediated by increased glucose availability to cancer cells (Fong et al., 2015). This evidence concerns the gene SLC2A1 and cancer.